Welcome to our dedicated page for IDEXX Laboratories SEC filings (Ticker: IDXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IDEXX Laboratories SEC filings document the formal record for a Nasdaq-listed animal-health diagnostics and software company. Form 8-K reports furnish quarterly and annual financial results, operating updates and exhibits tied to the company’s CAG Diagnostics, reference laboratory and veterinary product businesses.
The company’s filings also cover governance and capital-structure matters, including definitive proxy materials, executive compensation, board composition, officer transitions, equity-award disclosures and shareholder meeting items. Other material-event reports describe credit agreement amendments and registered common stock information, providing formal disclosure on IDEXX’s financing arrangements, corporate governance and reporting obligations.
IDEXX Laboratories reported a proposed sale of 1,758 common shares via Form 144, listed with Morgan Stanley Smith Barney LLC as the broker on 03/03/2026.
The shares are labeled as exercised shares with an exercise date of 08/06/2025. The excerpt also shows prior sales of 2,693 common shares on 02/25/2026 with an aggregate dollar amount of 1,781,530.72.
IDEXX Laboratories President and CEO Jonathan Jay Mazelsky exercised stock options for 23,523 shares of common stock at exercise prices of $141.6000 and $505.5300. He then sold 23,326 shares in multiple open-market trades at prices including $650.6695 and $663.0439, ending with 83,803.302 shares held directly.
IDEXX Laboratories Executive Vice President Nimrata Hunt reported an open-market sale of common stock. On February 26, 2026, Hunt sold 2,693 shares at a weighted average price of $661.5413 per share in open-market transactions. After the sale, Hunt directly owned 19,898.944 common shares and indirectly owned 160 shares jointly with a spouse. A footnote explains that the sale prices ranged from $661.35 to $661.8275 per share, with detailed trade breakdowns available upon request.
IDEXX Laboratories, Inc. files its Annual Report describing a diversified diagnostics business focused on companion animal health, water quality, and livestock, poultry and dairy testing, plus a smaller human point-of-care line. The company highlights extensive use of AI across analyzers, imaging and software, and a cloud ecosystem that connects in-clinic instruments with reference labs and telemedicine.
IDEXX reports $251.2 million of 2025 research and development expense, or 5.8% of consolidated revenue, up from $219.8 million (5.6%) in 2024 and $191.0 million (5.2%) in 2023. It notes significant regulatory oversight globally, reliance on some sole‑source suppliers, increasing PFAS and AI regulation, and strong human‑capital programs supporting about 11,000 employees in 34 countries.
IDEXX Laboratories Executive Vice President Michael G. Erickson reported multiple stock option exercises and related share sales. On February 17, 2026 and February 19, 2026, he exercised incentive and non-qualified stock options and received IDEXX common shares.
On February 17, 2026, he then sold 5,371 shares of common stock in open-market transactions at weighted average prices ranging from about $623.28 to $629.8625 per share. After these transactions, he directly held 12,693.351 shares of IDEXX common stock, including 184 vested but deferred restricted stock units.
IDEXX Laboratories director Sophie V. Vandebroek exercised a non-qualified stock option for 945 shares of common stock on February 17, 2026 at an exercise price of $333.90 per share, converting the derivative into common stock held directly.
On the same date, she executed open-market sales of 945 and 519 common shares at weighted average prices of $628.646 and $628.56 per share, respectively. After these transactions, she held 648 IDEXX common shares directly and 8,173 shares indirectly through the Sophie V. Vandebroek Revocable Trust.
IDEXX Laboratories executive Sharon E. Underberg reported multiple equity award activities. On February 12, 2026, she received grants of 3,738 non-qualified stock options, 162 incentive stock options, and 891 restricted stock units (RSUs), with the options and RSUs vesting in scheduled installments beginning February 14, 2027 and one option grant vesting on February 14, 2030.
On February 14, 2026, several prior RSU awards vested, converting into a total of 832 shares of common stock. To cover tax obligations, 251 shares of common stock were withheld at a price of $629.35 per share. After these transactions, she directly owned 6,940.654 shares of IDEXX common stock.
Smith Martin Alexander reported multiple insider transaction types in a Form 4 filing for IDXX. The filing lists transactions totaling 10,715 shares at a weighted average price of $629.35 per share. Following the reported transactions, holdings were 188 shares.